Institution
University of Milano-Bicocca
Education•Milan, Italy•
About: University of Milano-Bicocca is a education organization based out in Milan, Italy. It is known for research contribution in the topics: Population & Blood pressure. The organization has 8972 authors who have published 22322 publications receiving 620484 citations. The organization is also known as: Università degli Studi di Milano-Bicocca & Universita degli Studi di Milano-Bicocca.
Topics: Population, Blood pressure, Large Hadron Collider, Branching fraction, Ambulatory blood pressure
Papers published on a yearly basis
Papers
More filters
••
TL;DR: The strong correlation between serum ferritin and hepcidin at each point during the study indicates that iron itself or the kinetics of iron use in response to hypoxia may signal hePCidin down-regulation, suggesting the existence of hypoxIA-dependent mechanism(s) regulating storage iron mobilization.
134 citations
••
31 Dec 2010134 citations
••
TL;DR: Comparative, pragmatic, long-term and open trials should be done to show long- term efficacy and comparative features of the new antiepileptic drugs, and to better assess the effect on quality-of-life, cost-effectiveness, tolerability, and teratogenic potential.
Abstract: Summary Background Until the early 1990s six major compounds (carbamazepine, ethosuximide, phenobarbital, phenytoin, primidone, and valproic acid) were available for the treatment of epilepsy. However, these drugs have pharmacokinetic limitations, teratogenic potential, and a negative effect on cognitive functions that impairs the quality of patients' lives and limits the use of these drugs in some patients. In addition, 20–30% of patients are refractory to these drugs. Recent developments The development of ten new antiepileptic drugs (vigabatrin, felbamate, gabapentin, lamotrigine, topiramate, tiagabine, oxcarbazepine, levetiracetam, zonisamide, and pregabalin) has expanded treatment options. The newer drugs may be better tolerated, have fewer drug interactions, and seem to affect cognitive functions to a lesser extent than old drugs. Guidelines on the use of new antiepileptic drugs have been developed in the USA and in the UK. Both guidelines offer a clear picture of the efficacy, safety, and tolerability of the new antiepileptic drugs and agree on their use as add-on treatment in patients who do not respond to conventional drugs. The guidelines differ in the type and strength of recommendations. Whereas the US guidelines recommend treatment in newly diagnosed epilepsy with a standard drug or a new drug depending on the individual patient's characteristics, the UK guidelines recommend that a new antiepileptic drug should be considered only if there is no benefit from an old antiepileptic drug, an old drug is contraindicated, there is a previous negative experience with the same drug, or the patient is a woman of childbearing potential. Where next The limited amount of information on the new antiepileptic drugs may explain the discrepancies among the two guidelines and between these and other recommendations. Comparative, pragmatic, long-term and open trials should be done to show long-term efficacy and comparative features of the new antiepileptic drugs, and to better assess the effect on quality-of-life, cost-effectiveness, tolerability, and teratogenic potential. In addition, the conflicts should be resolved between the needs of the regulatory bodies and those of the treating physicians. Finally, there is a need for trial designs to be standardised.
134 citations
••
University of Graz1, Spanish National Research Council2, Providence College3, University of Sheffield4, University of Malta5, Tel Aviv University6, University of Miami7, Brown University8, French Institute of Health and Medical Research9, University of Bayreuth10, Roswell Park Cancer Institute11, Stockholm University12, University of Florence13, University Medical Center Groningen14, Rowan University15, University of Minho16, University of Porto17, Instituto de Biologia Molecular e Celular18, University of Bordeaux19, University of New South Wales20, University of Fribourg21, Texas A&M University22, Université libre de Bruxelles23, University of Lausanne24, National Research Council25, University of Parma26, University of Kent27, University of Manchester28, Royal Military College of Canada29, University of Osnabrück30, Heinrich Pette Institute31, Kaiserslautern University of Technology32, University of Alcalá33, University of Texas MD Anderson Cancer Center34, RMIT University35, University of Milano-Bicocca36, Sapienza University of Rome37, University of Ottawa38, Ottawa Hospital Research Institute39, University of Freiburg40, Chalmers University of Technology41, Technical University of Denmark42, University of Gothenburg43, Goethe University Frankfurt44, Ohio State University45, Centre national de la recherche scientifique46, Comenius University in Bratislava47, University of Minnesota48, University of Exeter49, University of Salzburg50, University of Kassel51, University of Málaga52, Moscow State University53, Free University of Berlin54, Katholieke Universiteit Leuven55, Concordia University56, Université Paris-Saclay57, Heidelberg University58, University of Wyoming59, University of Maryland, Baltimore60, Tsinghua University61, Paris Descartes University62, Cornell University63
TL;DR: Unified criteria for the definition of accidental, regulated, and programmed forms of cell death in yeast based on a series of morphological and biochemical criteria are proposed.
Abstract: Elucidating the biology of yeast in its full complexity has major implications for science, medicine and industry. One of the most critical processes determining yeast life and physiology is cel-lular demise. However, the investigation of yeast cell death is a relatively young field, and a widely accepted set of concepts and terms is still missing. Here, we propose unified criteria for the defi-nition of accidental, regulated, and programmed forms of cell death in yeast based on a series of morphological and biochemical criteria. Specifically, we provide consensus guidelines on the differ-ential definition of terms including apoptosis, regulated necrosis, and autophagic cell death, as we refer to additional cell death rou-tines that are relevant for the biology of (at least some species of) yeast. As this area of investigation advances rapidly, changes and extensions to this set of recommendations will be implemented in the years to come. Nonetheless, we strongly encourage the au-thors, reviewers and editors of scientific articles to adopt these collective standards in order to establish an accurate framework for yeast cell death research and, ultimately, to accelerate the pro-gress of this vibrant field of research.
134 citations
••
TL;DR: In patients with squamous cell carcinoma of the tongue, young age is an independent predictor of worse survival and survival analysis supports this conclusion.
133 citations
Authors
Showing all 9226 results
Name | H-index | Papers | Citations |
---|---|---|---|
Carlo Rovelli | 146 | 1502 | 103550 |
Giuseppe Mancia | 145 | 1369 | 139692 |
Marco Bersanelli | 142 | 526 | 105135 |
Teruki Kamon | 142 | 2034 | 115633 |
Marco Colonna | 139 | 512 | 71166 |
M. I. Martínez | 134 | 1251 | 79885 |
A. Mennella | 132 | 463 | 93236 |
Roberto Salerno | 132 | 1197 | 83409 |
Federico Ferri | 132 | 1376 | 89337 |
Marco Paganoni | 132 | 1438 | 88482 |
Arabella Martelli | 131 | 1318 | 84029 |
Sandra Malvezzi | 129 | 1326 | 84401 |
Andrea Massironi | 129 | 1115 | 78457 |
Marco Pieri | 129 | 1285 | 82914 |
Cristina Riccardi | 129 | 1627 | 91452 |